- Advertisement -

Related

Investing Alongside Peter Thiel

- Advertisement -

Stockholm (HedgeNordic) – In September of 2018, biotech start-up ATAI Life Sciences completed a Series A financing round in the amount of $24.4 million to make psychedelic drugs to treat mental health disorders. Long/short equity fund Coeli Absolute European Equity, founded and managed by Mikael Petersson (pictured) out of Malmö, invested close to $1 million in the Series A round alongside a select group of investors that also featured well-known entrepreneur and venture capitalist Peter Thiel.

“Our fund was one of only circa ten institutions globally who participated in the first round two years ago,” Petersson tells HedgeNordic. “It’s only two years ago since we had the privilege, as one of only ca 10 institutional investors, to participate in ATAI’s first funding,” Petersson writes in a LinkedIn post. “Since then so much progress has been made.”

“Our fund was one of only circa ten institutions globally who participated in the first round two years ago. Since then so much progress has been made.”

After completing its Series B financing round of $43 million in March of this year, ATAI Life Sciences announced earlier this week the successful closing of its $125 million Series C financing round, which included $32 million of convertible debt that converted in connection with the Series C. The round was co-led by the family office of ATAI’s founder Christian Angermayer, Peter Thiel, and Catalio Capital Management, as well as other existing and new investors.

The proceeds from the financing will be primarily used to fund pre-clinical and clinical development of ATAI’s existing mental health programs, as well as expand its drug candidate pipeline and further advance ATAI’s platform technologies. ATAI Life Sciences operates as a drug development platform, aiming to acquire, incubate and develop psychedelics and other drugs to treat depression, anxiety, addiction and other mental health conditions.

According to an industry source cited by CNBC, the plan is to take ATAI Life Sciences public next year at a valuation of between $1 and $2 billion. “I would say we have all avenues open right now and haven’t yet finally decided which one we will take,” Florian Brand, the CEO & Co-Founder of ATAI Life Sciences, told CNBC on the future of ATAI.

Coeli Absolute European Equity can allocate up to ten percent of its portfolio to unlisted equities. “We have a mandate to invest up to ten percent in unlisted equities, but in reality, we target an allocation of five percent to this space on average,” Petersson recently told HedgeNordic. “We have maintained an allocation to unlisted stocks between two to four percent since the fund’s inception in early 2018.”

“We at the Coeli Absolute European Equity Fund are obviously very proud and happy investors and we look forward to a new exciting year in 2021.”

Before the Series C financing round, Coeli Absolute European Equity’s investment in ATAI Life Sciences accounted for about two percent of the fund’s assets under management, which currently stand at €74.3 million. “We are very happy and proud of the development journey of the firm,” Petersson tells HedgeNordic. “We at the Coeli Absolute European Equity Fund are obviously very proud and happy investors and we look forward to a new exciting year in 2021,” he added. “We are looking forward to an anticipated IPO next year.”

 

Picture by Rickard Kilström

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Redwheel Opens Copenhagen Office to Strengthen Nordic Presence

Specialist investment manager Redwheel is strengthening its presence in the Nordic region with the opening of a Copenhagen office, establishing a local base from...

Major Redemption Triggers Nordea Fund Liquidation

Nordea has announced the liquidation of its Luxembourg-domiciled multi-asset absolute return fund MA Liquid Alternative I Fund following “the receipt of a massive redemption...

ALCUR Turns to ISEC for Fund Services

Stockholm-based boutique ALCUR Fonder has appointed ISEC as its fund administrator and risk manager, as the firm looks to strengthen its operational infrastructure and...

Nordic Hedge Funds Start Final Quarter in the Red

Nordic hedge funds entered the final quarter of the year on the back foot. The Nordic Hedge Index fell 1.4 percent in October, with...

Afa Försäkring Puts Operational Value Creation at the Centre of Private Equity

The challenging private equity environment, marked by higher financing costs, slower distributions and difficult exit conditions, is putting greater pressure on managers to demonstrate...

Thorbjörn Wallentin Parts Ways with OQAM as Credit Takes Centre Stage

After more than a decade helping build Malmö-based asset management firm OQAM, co-founder and Chief Investment Officer Thorbjörn Wallentin is stepping away from his...

Allocator Interviews

Voices

Request for Proposal

- Advertisement -